19 results about "Tetrandrine" patented technology

The invention discloses a method for extracting tetrandrine in stephania tetrandra, which comprises the following steps: (1) mixing stephania tetrandra and ethanol, extracting, collecting filtrate, and removing ethanol to obtain stephania tetrandra extract; (2) mixing organic matters, inorganic salts and water to obtain an aqueous two-phase system; and (3) adding the stephania tetrandra extract into the aqueous two-phase system, and then carrying out ultrasonic treatment, shaking extraction and centrifugation to obtain an upper-phase system and a lower-phase system which contain tetrandrine. According to the method for extracting the tetrandrine in the stephania tetrandra, an aqueous two-phase extraction method and an ultrasonic technology are combined, the extraction rate of the tetrandrine in the stephania tetrandra is taken as a target, and an extraction and separation process of the tetrandrine in the stephania tetrandra extract is optimized by adopting the aqueous two-phase extraction method. The tetrandrine extracted by the ultrasonic-assisted aqueous two-phase method is high in yield and low in solvent residue. The extract obtained by the method has a good inhibition effect on pancreatic lipase.

The invention provides a drug-drug co-amorphous substance co-carrying active traditional Chinese medicine components, namely breviscapine and cepharanthine. The prescription of the drug-drug co-amorphous substance does not contain any auxiliary materials, the preparation method is simple, convenient and efficient, special processes and equipment are not needed, the cost is low, and industrialization is easy. The prepared breviscapine-cepharanthine powder is in an amorphous state, the water solubility of indissolvable drugs breviscapine and cepharanthine can be improved at the same time, the in-vitro antioxidant activity is superior to that of raw drugs, further preparation forming is facilitated, and the bioavailability is improved.

The application discloses a high-drug-loading tetrandrine liposome as well as a preparation method and application thereof. The liposome comprises the following components in parts by weight: tetrandrine 1.5-2.5 parts, a pH regulator 0.6-1 part, lecithin 3-5 parts, cholesterol 0.1-0.3 parts, a cosolvent 3-6 parts, an antioxidant 0.5-1 part, oil 6-10 parts, water 25-30 parts and a polyhydric alcohol 35-55 parts. The drug loading of the tetrandrine liposome prepared by the application can be as high as 1.5-2.5 %, which is significantly higher than that of the tetrandrine liposome prepared by the prior art. The tetrandrine liposome has the following test results: a clear appearance, good stability, a raw solution particle size of 100-400 nm, a raw solution PDI (polydispersity index) of 0.5 or less and an encapsulation rate of 80 % or more, and meets the requirements for cosmetic use. Moreover, the tetrandrine liposome is proved to be completely applicable to cosmetics through tests on irritation, hyaluronidase inhibition effect, transdermal absorption effect and inflammatory factor secretion inhibition.

The invention belongs to the technical field of medicines, and discloses application of combination of bicyclol and tetrandrine in preparation of a medicine for treating silicosis.

This invention relates generally to injectable drug delivery systems and methods of preparing same, and in particular to drug delivery systems comprising biodegradable polymeric nanogel formulations that form a depot (gel) in the body once injected, and can release therapeutic agents with enhanced extended-release times in the subject being treated. The polymer matrix drug delivery systems of the subject invention are comprised of a biodegradable polymer, a solvent or a combination of solvents, an alkylphenol, and therapeutic agents such as insulin, tetrandrine, other small molecule drugs (preferably hydrophobic drugs) to treat a variety of diseases including diabetes and hearing loss. A preferred alkylphenol is meta cresol which has demonstrated importance for dissolving and stabilizing the therapeutic agents, and forming gels with better shape and controlled drug release after injection.

The invention belongs to the technical field of biological medicines, and discloses application of tetrandrine in preparation of a medicine for inhibiting human papilloma virus infection. The invention discloses an application of tetrandrine or a pharmaceutically acceptable salt thereof in preparation of an anti-HPV (human papillomavirus) infection medicine. The application of the traditional Chinese medicine monomer component tetrandrine or the pharmaceutically acceptable salt thereof in preparation of the anti-HPV (especially high-risk HPV16) infection medicine is found and verified for the first time, the inhibition effect of the tetrandrine or the pharmaceutically acceptable salt thereof has the characteristic of concentration dependence, and a brand new technical path is opened up for research and development of the anti-HPV medicine.

The invention relates to application of ulinastatin and tetrandrine in preparation of a medicine for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of biological medicine. The invention provides application of ulinastatin combined with tetrandrine in preparation of a medicine for preventing and / or treating radiation-induced lung injury. The ulinastatin and the tetrandrine are combined to be used as a medicine for treating mice suffering from radiation-induced lung injury, and the result shows that the ulinastatin and the tetrandrine have very good treatment and prevention effects on the radiation-induced lung injury, and the ulinastatin and the tetrandrine are non-toxic to lung cells; growth and development of normal lung cells cannot be inhibited, the treatment effect does not have dose dependence, the content of pro-inflammatory cytokines TNF-alpha and IL-6 can be remarkably reduced, the symptom of lung tissue inflammation can be relieved, and the survival rate of mice suffering from radiation-induced lung injury can be increased.

The invention discloses tetrandrine-oleic acid composite ionic liquid as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The tetrandrine-oleic acid compound ionic liquid is prepared from tetrandrine and oleic acid, and the preparation method comprises the following steps: adding tetrandrine and oleic acid into an organic solvent for dissolving, heating and stirring for reaction to generate a solution, and then removing the organic solvent in the solution to obtain the tetrandrine-oleic acid compound ionic liquid. According to the tetrandrine-oleic acid composite ionic liquid synthesized through an acid-base neutralization reaction, the original molecular structure of tetrandrine is reserved, the water solubility of tetrandrine is improved, and the in-vitro transdermal amount of tetrandrine is greatly increased while safety is guaranteed.

The application belongs to the technical field of medicine multistage purification, and discloses a tetrandrine multistage purification device containing ion liquid modified chromatography medium, which comprises chromatography columns, the chromatography columns are provided with three, upper and lower sealing plates are respectively fixedly connected to the top and bottom of the three chromatography columns, the cooperation of the structures of the horizontal plate, ring block, movable ring plate, vertical rod, upper rotary disc and lower rotary disc in the rotary switching mechanism is provided, double holes are formed in the upper rotary disc, three circular holes are formed in the lower rotary disc, when the horizontal plate rotates, the upper rotary disc and the lower rotary disc are synchronously rotated by the vertical rod, the double holes are aligned with the inlet of the next chromatography column, and the three circular holes are aligned with the outlet of the corresponding chromatography column, so that the seamless station switching between the multiple chromatography columns is facilitated, the operator only needs to rotate the horizontal plate to complete the synchronous switching of the inlet and outlet of the chromatography column, the chromatography column does not need to be stopped and balanced, the purification process is continuous and uninterrupted, and the production efficiency is greatly improved.

This invention belongs to the field of biopharmaceutical technology, specifically disclosing the application of tetrandrine in the preparation of anti-AKAV drugs. This invention determines the safe concentration range of tetrandrine on MDBK cells and discovers through RT-qPCR, WB, and IFA that tetrandrine can act as an inhibitor of AKAV virus. A concentration of 10 μM of tetrandrine has a significant inhibitory effect on AKAV virus, providing a new candidate drug for the prevention and treatment of AKAV virus infection.

The invention discloses a nanoparticle. The nanoparticle comprises tetrandrine, folic acid co-loaded nano-liposome and a hyaluronidase layer, wherein the surface of the co-loaded nano-liposome is coated with the hyaluronidase layer. The invention also discloses a preparation method of the nanoparticle, and the preparation method comprises the following steps: uniformly mixing a tetrandrine and folic acid co-loaded nano-liposome aqueous dispersion and a hyaluronidase aqueous solution, and carrying out electrostatic adsorption and solid-liquid separation to obtain the nanoparticle. The invention further discloses freeze-dried powder of the nanoparticles, which comprises the nanoparticles and chitosan quaternary ammonium salt. The invention also discloses a preparation method of the nanoparticle freeze-dried powder. The invention further discloses application of the nanoparticles and the nanoparticle freeze-dried powder in preparation of drugs for inhibiting and / or treating pulmonary fibrosis. The nanoparticle freeze-dried powder containing tetrandrine and folic acid provided by the invention has a good effect of inhibiting pulmonary fibrosis.

The application discloses application of tetrandrine in preparation of a medicine for preventing and treating porcine coronavirus, and the effective component of the medicine is tetrandrine / tetrandrine and methylhesperidin. It is found by the application that tetrandrine or tetrandrine and methylhesperidin can significantly inhibit replication of the porcine coronavirus at a low concentration, and the medicine prepared by using tetrandrine or tetrandrine and methylhesperidin at a low concentration can effectively prevent and treat porcine transmissible gastroenteritis virus or porcine epidemic diarrhea virus.

The present application relates to the medical technology, specifically relates to tetrandrine preparation method. The present application utilizes the ultrafiltration membrane to extract tetrandrine A and B from the tetrandrine powder first, then through the solvent purification and refining processes, high quality tetrandrine B with the purity of 99.5% or more and the maximum single impurity of 0.05% or less is obtained.

The invention belongs to the technical field of eluent spraying, and discloses a chromatographic column eluent accurate distribution spraying assembly for tetrandrine separation, which comprises a bottom plate, in the process that a chromatographic column drives a top plate and a liquid injection pump to rotate, when the liquid injection pump rotates to the bottom of equipment, the eluent can flow to the top plate, and when the liquid injection pump rotates to the bottom of the equipment, the eluent can flow to the top plate; a camera detector can detect the amount of eluent which is not mixed, when the amount of the unmixed eluent is too large, the camera detector can control the operation efficiency of an electric telescopic rod to be increased, the electric telescopic rod drives a piston plate to ascend in an annular shell, negative pressure is generated in the annular shell, the eluent enters the annular shell through the negative pressure, and then the eluent enters the annular shell; and when an electric telescopic rod drives a piston plate to move reversely, the piston plate extrudes the eluent in an annular shell, so that the eluent enters a round shell through a conical pipe and enters a sprayer through the round shell, and then secondary spraying is carried out.

The invention provides a tetrandrine and baicalin self-assembled nano-particle. The tetrandrine and baicalin self-assembled nano-particle is prepared from the following materials: tetrandrine and baicalin. The molar ratio of the tetrandrine to the baicalin is preferably 1: 2, and the concentrations of the tetrandrine and the baicalin are respectively 1.12 mM and 2.24 mM. A preparation method of tetrandrine and baicalin self-assembled nanoparticles comprises the following steps: weighing tetrandrine and baicalin according to a required molar ratio, jointly dissolving the tetrandrine and the baicalin in deionized water, stirring at a constant temperature of 100 DEG C for 1 hour, naturally cooling to room temperature to complete a self-assembly process, and centrifuging to remove large aggregates to obtain the tetrandrine and baicalin self-assembled nanoparticles. And dialyzing and purifying to obtain the self-assembled nanoparticles. The tetrandrine and baicalin self-assembled nanoparticles can be used for treating silicosis and can enhance the improvement effect on lung functions, silicosis nodules, alveolar structures, lung indexes, hydroxyproline content and silicosis fibrosis, and a nano drug delivery system can effectively eliminate renal toxicity and hepatotoxicity risks of tetrandrine.

The invention provides an application of tetrandrine in inhibiting porcine reproductive and respiratory syndrome virus and also provides a product for resisting the porcine reproductive and respiratory syndrome virus, which comprises the tetrandrine. Wherein the dosage of the tetrandrine or the derivative of the tetrandrine on the PAM cell is 4-12.5 mu M; and the molecular weight on MARC-145 cells is 7-25 [mu] M. The antagonistic action and the action mechanism of the tetrandrine on the PRRSV are found for the first time, when the concentration of the tetrandrine reaches 7 mu M or above, virus proliferation can be effectively inhibited, and meanwhile, the concentration does not cause obvious influence on cell activity. The tetrandrine provided by the invention has important significance in application of inhibiting the PRRSV in the field of resisting the PRRSV, and a new alternative medicine is provided for preventing and treating the PRRSV.

The application synthesizes a series of novel ligustrazine-porphyrin derivatives with ligustrazine and porphyrin as lead compounds, combines porphyrin PDT and ligustrazine chemotherapy, realizes synergistic anticancer of photodynamic therapy (PDT) and chemotherapy, and obtains a series of antitumor drugs with better activity and smaller side effects, and has potential application value.

The invention discloses an azelaic acid and ligustrazine eutectic crystal and a preparation method thereof, and belongs to the technical field of eutectic crystals, and the preparation method is characterized by comprising the following steps: uniformly mixing azelaic acid and ligustrazine according to a specific feeding ratio, transferring into a closed reactor, placing in a certain atmosphere condition, ensuring a water-free and oxygen-free environment, and carrying out constant-temperature stirring at 70-115 DEG C, so as to obtain the azelaic acid and ligustrazine eutectic crystal. The stirring time is 1-10 hours, cooling to room temperature to obtain a solid product, and grinding the solid product to obtain a white solid product, namely the azelaic acid / ligustrazine eutectic crystal. According to the eutectic system, the water solubility of the azelaic acid can be remarkably improved, and meanwhile through the synergistic effect of the azelaic acid and ligustrazine, the permeability, antibacterial activity, oxidation resistance and other effects of the azelaic acid are remarkably improved.

This invention provides an application of a drug to inhibit silicosis fibrosis. This invention demonstrates that rhodioloside can inhibit the expression levels of fibrosis-related proteins Collagen 1 and α-SMA in SiO2-exposed mice, reduce the number of diffuse high-density shadows and characteristic silicotic nodules in the interstitial lung fields, and decrease the area of ​​diffuse collagen fiber deposition. Simultaneously, rhodioloside can also inhibit TGF-β-induced expression levels of Collagen 1 and α-SMA in NIH / 3T3 cells, inhibiting the transdifferentiation of fibroblasts into myofibroblasts. Furthermore, the research results show that the effect of the same dose of rhodioloside is comparable to, or even superior to, the current first-line clinical drug for alleviating silicosis fibrosis, tetrandrine. These research results prove that rhodioloside can effectively alleviate silicosis fibrosis.